To ensure that commercial biomanufacturing processes are in a state of control, life sciences companies must create and successfully execute initiatives to meet expanding monitoring guidelines.
Management teams at pharmaceutical, biotech and medical device companies commonly receive directives associated with data monitoring which cause various challenges to arise with developing and maintaining successful monitoring programs.
Read this white paper to learn about a maturity model to help companies navigate the major steps of implementing a global monitoring plan for Continued Process Verification (CPV), and why CPV is becoming increasingly critical for meeting the monitoring needs of life sciences organizations.
No comments:
Post a Comment